Xcellerex, Inc. has begun construction of a state-of-the-art current good manufacturing practices-compliant FlexFactory biomanufacturing facility at its headquarters in Marlborough, MA.
Xcellerex, Inc. has begun construction of a state-of-the-art current good manufacturing practices-compliant FlexFactory biomanufacturing facility at its headquarters in Marlborough, MA. Construction will be completed in September 2010.
The facility, the second FlexFactory at the Marlborough site, will expand Xcellerex's capacity to provide bridge biomanufacturing services for clients that are planning or building their own FlexFactory facilities. The plant also will support Xcellerex's contract manufacturing operations. The new facility will feature 2,000 L Xcellerex XDR single-use bioreactors and modular single-use downstream unit operations through bulk-product.
Xcellerex's FlexFactory is a portable manufacturing platform, based on the application of single-use technologies, controlled environmental modules, and process automation including electronic batch records.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Oligonucleotide Analysis in Pharmaceutical Quality Control
January 14th 2025Melting point determination using ultraviolet-visible (UV-Vis) spectrophotometry can be used as a sequence-specific method for identifying therapeutic oligonucleotides in pharmaceutical quality control. This method offers a simple, highly selective approach to differentiate between isomers and ensure the integrity of oligonucleotide active pharmaceutical ingredients (APIs) and drug products.